奥沙利铂联合长春瑞滨治疗铂耐药卵巢癌患者的临床研究
|
摘要
目的研究奥沙利铂联合长春瑞滨治疗铂耐药卵巢癌患者的临床效果。方法选取铂耐药卵巢癌患者78例,根据数字随机量表法分为观察组及对照组,各39例。对照组患者给予伊立替康治疗,观察组则给予奥沙利铂联合长春瑞滨治疗。对比2组效果。结果 2组治疗后RR率差异无统计学意义(P>0.05)。2组各项不良反应发生率对比,差异均无统计学意义(P均>0.05)。观察组6个月体质量减轻>10%的发生率为33.33%(13/39),显著低于对照组的69.23%(27/39),差异有统计学意义(P<0.05)。观察组无进展生存期及总生存期分别为(32.2±7.8)周、(76.8±21.3)周,均显著高于对照组的(22.8±6.3)周、(61.6±14.2)周,差异均有统计学意义(P均<0.05)。结论奥沙利铂联合长春瑞滨治疗铂耐药卵巢癌具有较好疗效,且不会增加不良反应发生率,可延长患者生命。
Objective To study the efficacy of the combined therapy with vinorelbine and oxaliplatin for platinum resistance in patients with ovarian cancer. Methods 78 cases of patients with platinum-resistant ovarian cancer,according to the digital random scaling were divided into the observation group and the control group,39 cases in each group. The control group was given irinotecan for the treatment,the observation group were given oxaliplatin and vinorelbine treatment,compared the 2 groups of effect. Results RR rates of the 2 groups had no significant difference after treatment( P > 0. 05). There had no significant difference in the incidence of adverse reactions( P > 0. 05). In the observation group,6 months body quality > 10% rate was 10%( 13/39),which was significantly lower than the control group,69. 23%( 27/39),the difference was statistically significant( P <0. 05). In the observation group,progression-free survival and overall survival were respectively( 32. 2 ± 7. 8),( 76. 8 ± 21. 3)weeks,which were significantly higher than that of the control group( 22. 8 ± 6. 3),( 61. 6 ± 14. 2) weeks,the differences were statistically significant( all P < 0. 05). Conclusion Combined therapy with Vinorelbine and oxaliplatin for platinum-resistant ovarian cancer has good curative effect,and will not increase the incidence of adverse reaction,can prolong patients' life.
Objective To study the efficacy of the combined therapy with vinorelbine and oxaliplatin for platinum resistance in patients with ovarian cancer. Methods 78 cases of patients with platinum-resistant ovarian cancer,according to the digital random scaling were divided into the observation group and the control group,39 cases in each group. The control group was given irinotecan for the treatment,the observation group were given oxaliplatin and vinorelbine treatment,compared the 2 groups of effect. Results RR rates of the 2 groups had no significant difference after treatment( P > 0. 05). There had no significant difference in the incidence of adverse reactions( P > 0. 05). In the observation group,6 months body quality > 10% rate was 10%( 13/39),which was significantly lower than the control group,69. 23%( 27/39),the difference was statistically significant( P <0. 05). In the observation group,progression-free survival and overall survival were respectively( 32. 2 ± 7. 8),( 76. 8 ± 21. 3)weeks,which were significantly higher than that of the control group( 22. 8 ± 6. 3),( 61. 6 ± 14. 2) weeks,the differences were statistically significant( all P < 0. 05). Conclusion Combined therapy with Vinorelbine and oxaliplatin for platinum-resistant ovarian cancer has good curative effect,and will not increase the incidence of adverse reaction,can prolong patients' life.
引文
[1]Monk BJ,Herzog TJ,Tewari KS,et al.Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients[J].Curr Pharm Des,2016,22(30):4714-4728.
[2]Wei Z,Liu Y,Wang Y,et al.Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation,invasion,and drug resistance of ovarian cancer[J].Med Oncol,2016,33(11):126-126.
[3]Luo Y,Lee M,Kim HS,et al.Effect of neoadjuvant chemotherapy on platinum resistance in stageⅢC andⅣepithelial ovarian cancer[J].Medicine(Baltimore),2016,95(36):4797-4798.
[4]Wu WJ,Wang Q,Zhang W,et al.Identification and prognostic value of differentially expressed proteins of patients withplatinum resistance epithelial ovarian cancer in serum[J].Zhonghua Fu Chan Ke Za Zhi,2016,51(7):515-523.
[5]吴珈悦.黏液性卵巢癌的诊治进展[J].国际妇产科学杂志,2015,42(3):260-264.
[6]刘德春,娄艳辉,王灵芝,等.沉默miR-21表达对顺铂耐药卵巢上皮性癌细胞耐药性的影响及其机制研究[J].中华妇产科杂志,2016,51(4):300-303.
[7]梁宏,赵洪波,赵庆华,等.基于生物信息学技术挖掘顺铂耐药卵巢癌潜在治疗药物[J].医学信息,2016,29(25):3-4.
[8]林蔚.伊立替康治疗复发性铂类耐药性卵巢癌的疗效观察[J].世界临床医学,2016,10(17):95-95.
[9]李春青,牛思强.恩度联合伊立替康治疗复发性卵巢癌疗效分析[J].中国现代药物应用,2014,34(13):11-12.
[10]高景阳,黄淑华.卵巢癌铂类耐药治疗的研究进展[J].新医学,2016,47(5):299-302.
[11]朱慧婷,高嵩.托泊替康单药及与奥沙利铂联用治疗铂耐药性卵巢癌的临床研究[J].实用药物与临床,2016,19(2):144-147.
[12]唐三元,殷耒兰,陈琳,等.长春瑞滨联合奥沙利铂二线治疗复发性卵巢癌的临床观察[J].中国现代医生,2013,51(14):80-81.
[13]戴玲玲.奥沙利铂神经系统毒性与防治[J].中国实用医药,2013,8(23):131-132.
[14]王祎晨,徐小仙,孙海燕,等.奥沙利铂联合氟尿嘧啶和亚叶酸钙治疗铂耐药复发卵巢癌初探[J].临床合理用药杂志,2012,5(35):27-28.
[15]姚晓芳,周爱智.吉西他滨联合奥沙利铂治疗铂类耐药性复发卵巢癌[J].中国实用医刊,2012,39(6):117-118.
[2]Wei Z,Liu Y,Wang Y,et al.Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation,invasion,and drug resistance of ovarian cancer[J].Med Oncol,2016,33(11):126-126.
[3]Luo Y,Lee M,Kim HS,et al.Effect of neoadjuvant chemotherapy on platinum resistance in stageⅢC andⅣepithelial ovarian cancer[J].Medicine(Baltimore),2016,95(36):4797-4798.
[4]Wu WJ,Wang Q,Zhang W,et al.Identification and prognostic value of differentially expressed proteins of patients withplatinum resistance epithelial ovarian cancer in serum[J].Zhonghua Fu Chan Ke Za Zhi,2016,51(7):515-523.
[5]吴珈悦.黏液性卵巢癌的诊治进展[J].国际妇产科学杂志,2015,42(3):260-264.
[6]刘德春,娄艳辉,王灵芝,等.沉默miR-21表达对顺铂耐药卵巢上皮性癌细胞耐药性的影响及其机制研究[J].中华妇产科杂志,2016,51(4):300-303.
[7]梁宏,赵洪波,赵庆华,等.基于生物信息学技术挖掘顺铂耐药卵巢癌潜在治疗药物[J].医学信息,2016,29(25):3-4.
[8]林蔚.伊立替康治疗复发性铂类耐药性卵巢癌的疗效观察[J].世界临床医学,2016,10(17):95-95.
[9]李春青,牛思强.恩度联合伊立替康治疗复发性卵巢癌疗效分析[J].中国现代药物应用,2014,34(13):11-12.
[10]高景阳,黄淑华.卵巢癌铂类耐药治疗的研究进展[J].新医学,2016,47(5):299-302.
[11]朱慧婷,高嵩.托泊替康单药及与奥沙利铂联用治疗铂耐药性卵巢癌的临床研究[J].实用药物与临床,2016,19(2):144-147.
[12]唐三元,殷耒兰,陈琳,等.长春瑞滨联合奥沙利铂二线治疗复发性卵巢癌的临床观察[J].中国现代医生,2013,51(14):80-81.
[13]戴玲玲.奥沙利铂神经系统毒性与防治[J].中国实用医药,2013,8(23):131-132.
[14]王祎晨,徐小仙,孙海燕,等.奥沙利铂联合氟尿嘧啶和亚叶酸钙治疗铂耐药复发卵巢癌初探[J].临床合理用药杂志,2012,5(35):27-28.
[15]姚晓芳,周爱智.吉西他滨联合奥沙利铂治疗铂类耐药性复发卵巢癌[J].中国实用医刊,2012,39(6):117-118.